Cynata Therapeutics Limited (CYNATA THR FPO [CYP]) aktie

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.